ABCA7 and Alzheimer disease: This in vivo model showed a reduced response to inflammation, lipid metabolism, Aβ pathology and neuronal damage, demonstrating that this microglial ABCA7 variant may confer a gain of function and provide a protective effect against AD-related pathology [64].